The FDA has approved the fourth biosimilar to infliximab, infliximab-axxq, for all eligible indications of the biologic product.

Avsola (infliximab-axxq, Pfizer), a biosimilar to Remicade (infliximab, Janssen), is a tumor necrosis factor blocker intended for patients with rheumatoid arthritis, in combination with methotrexate, as well as for patients with Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.